ACRV
Acrivon Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.85
+8.82%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.72
From 52W high−38.54%
Volume475579.00
Market cap$79.28M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.72
From 52W high
−38.54%
Volume
475579.00
Market cap
$79.28M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
45.3
MomentumView details →
1D Return
+8.82%
YTD Return
−23.24%
SummaryUpdated Jun 1, 2026
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Watertown, Massachusetts. The company went public in November 2022 and focuses on developing precision oncology medicines using its proprietary proteomics-based platform to identify patients most likely to respond to specific cancer treatments. Acrivon operates in the competitive biotechnology sector, specifically targeting DNA damage response pathways in cancer cells.
Similar companies
Latest newsMore news →
No recent news for ACRV.